FY2026 Earnings Forecast for IONS Issued By Leerink Partnrs

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Analysts at Leerink Partnrs reduced their FY2026 earnings per share estimates for Ionis Pharmaceuticals in a report released on Monday, February 24th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($3.25) per share for the year, down from their prior forecast of ($3.24). The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share. Leerink Partnrs also issued estimates for Ionis Pharmaceuticals’ FY2027 earnings at ($1.62) EPS.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.46. The firm had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The business’s revenue was down 30.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.12 EPS.

A number of other equities research analysts have also commented on IONS. Citigroup reduced their price objective on shares of Ionis Pharmaceuticals from $67.00 to $64.00 and set a “buy” rating on the stock in a research note on Thursday, February 20th. StockNews.com downgraded Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Piper Sandler dropped their price objective on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Wells Fargo & Company decreased their target price on Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research note on Thursday, November 7th. Finally, William Blair reiterated an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $60.00.

Ionis Pharmaceuticals Stock Performance

NASDAQ:IONS opened at $31.35 on Thursday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. Ionis Pharmaceuticals has a fifty-two week low of $30.23 and a fifty-two week high of $52.34. The company has a 50 day simple moving average of $33.23 and a two-hundred day simple moving average of $37.94. The company has a market capitalization of $4.98 billion, a PE ratio of -10.31 and a beta of 0.34.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, EVP Patrick R. O’neil sold 6,165 shares of the firm’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $31.62, for a total value of $194,937.30. Following the completion of the transaction, the executive vice president now directly owns 57,452 shares of the company’s stock, valued at $1,816,632.24. This trade represents a 9.69 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Eric Swayze sold 7,154 shares of the company’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $32.84, for a total value of $234,937.36. Following the completion of the transaction, the executive vice president now owns 45,670 shares in the company, valued at $1,499,802.80. This represents a 13.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 111,816 shares of company stock valued at $3,603,914. Company insiders own 2.71% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of IONS. Signaturefd LLC increased its stake in Ionis Pharmaceuticals by 160.0% in the fourth quarter. Signaturefd LLC now owns 949 shares of the company’s stock valued at $33,000 after acquiring an additional 584 shares during the last quarter. Huntington National Bank increased its position in shares of Ionis Pharmaceuticals by 193.5% during the 4th quarter. Huntington National Bank now owns 951 shares of the company’s stock valued at $33,000 after purchasing an additional 627 shares during the last quarter. Lindbrook Capital LLC raised its holdings in shares of Ionis Pharmaceuticals by 183.8% during the 4th quarter. Lindbrook Capital LLC now owns 1,036 shares of the company’s stock valued at $36,000 after buying an additional 671 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in Ionis Pharmaceuticals in the 3rd quarter worth approximately $40,000. Finally, Prospera Private Wealth LLC purchased a new stake in Ionis Pharmaceuticals in the third quarter worth approximately $42,000. Hedge funds and other institutional investors own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.